Epilepsy - KOL Insight

Description

KOLs see the potential in Marinus Pharmaceuticals' Ztalmy for treating Lennox-Gastaut syndrome, but in what other setting do they perceive it might provide value, and what factors could limit its uptake? Experts accept that Eisai's Fycompa is an effective treatment for both focal and generalized epilepsies, but what safety concerns do they express? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to KOL Bulletins.

Executive summary (11)

Future treatment paradigm for epilepsy

Research objectives (1)

Sodium channel blockers (20)

Marketed therapies (20)
- Carbamazepine-related anti-seizure drugs (5)
- Vimpat (lacosamide; UCB) (6)
- Xcopri/Ontozry (cenobamate; SK Life Science) (9)

Neuromodulators (5)

Marketed therapies (5)
- Briviact (brivaracetam; UCB) (5)

GABAergic mechanisms (20)

Marketed therapies (20)
- Benzodiapines (rescue medications) (8)
- Ztalmy (ganaxolone; Marinus Pharmaceuticals) (12)

Other modes of action (24)

Marketed therapies (24)
- Epidiolex/Epidyolex (cannabidiol; Jazz Pharmaceuticals) (8)
- Fintepla (fenfluramine; UCB) (6)
- Fycompa (perampanel; Eisai) (10)

Late-stage products (31)

Pipeline therapies (31)
- Belviq (lorcaserin; Eisai) (14)
- Soticlestat (Takeda) (10)
- Carisbamate (SK Life Science) (7)

Early-stage products (17)

Pipeline therapies (17)
- ACT-709478/NBI-827104 (Neurocrine Biosciences) (5)
- XEN1101 (Xenon Pharmaceuticals) (7)
- Clemizole (EPX-100; Epygenix Therapeutics) (5)